Jeremy Launders

Jeremy Launders is a biopharmaceutical executive with over 25 years of leadership experience across the biotechnology, pharmaceutical, and medical device sectors. Since October 2020, he has served as Chief Executive Officer and President of the Management Board of Bioton S.A., a leading European producer of recombinant human insulin and a provider of comprehensive diabetes care solutions.

He holds a degree in Applied Biological Sciences and Biotechnology from Technological University Dublin and began his career in highly regulated manufacturing and technical operations. Over the years, he progressed through senior leadership roles at global organizations including Baxter International, Pfizer Global Supply, and DiaSorin, where he built extensive expertise in biologics production, quality systems, and international supply chain management.

His earlier career was marked by hands-on leadership in complex manufacturing environments, including the production of vaccines, sterile injectables, molecular diagnostics, and biologically derived APIs. He has led large-scale operational transformations, regulatory inspections, and cross-border technology transfers, as well as supporting product commercialization in highly regulated markets such as the U.S., Canada, and the European Union.

Prior to joining Bioton, Jeremy served as Vice President of Operations and Supply Chain at Bimeda, where he was responsible for end-to-end operations across Europe and Canada. In this role, he successfully led strategic product implementations, strengthened supply chain resilience, and delivered multiple regulatory approvals, while optimizing performance in complex, compliance-driven environments.

Since joining Bioton, Jeremy has led the company through a period of transformation and resilience amid global healthcare and supply chain disruptions. Under his leadership, the company has strengthened its position as a key European insulin manufacturer, ensuring continuity of supply during periods of global shortage and geopolitical uncertainty. He has driven operational efficiencies, advanced modernization initiatives, and expanded the company’s international reach through partnerships and market access strategies.

He has also championed the development of biosimilars and the integration of digital health solutions, while advocating for the responsible use of artificial intelligence in drug development and regulatory processes. A strong proponent of European pharmaceutical independence, he emphasizes the importance of regional production of APIs and finished medicines.

Jeremy is recognized for his patient-first approach, commitment to quality and cost-effectiveness, and focus on sustainable innovation. He promotes a collaborative and transparent leadership culture, prioritizing employee engagement, resilience, and long-term value creation, while positioning Bioton for continued growth in diabetes care, including expansion into oral therapies and medical devices.